Abstract

The goal ofthe University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Career Development Program (CDP) is to develop knowledgeable, well-trained scientists experienced in multidisciplinary research for future studies in translational lymphoma research. The provision of ample opportunities for training and career enhancement is a top priority ofthe University of lowa and Mayo Clinic scientific communities. The CDP represents a key

Public Health Relevance

The UI/MC SPORE CDP will provide supportfor integrated training and education to new investigators committed to careers in lymphoma translational research. The CDP is designed to provide breadth and flexibility to awardees who require additional research knowledge and skills in order to compete for independent extramural grant support and contribute to the UI/MC SPORE. The CDP has been very successful over the last 9 years at accomplishing these goals. The CDP will continue as a research experience under the mentorship of established SPORE investigators and supported by SPORE-funded Core resources.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097274-11S1
Application #
8561366
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
2002-09-20
Project End
2017-06-30
Budget Start
2012-09-12
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$10,063
Indirect Cost
$3,399

  Institution

Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242

  Publications

Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598
Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Pophali, Priyanka A; Ip, Andrew; Larson, Melissa C et al. (2018) The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93:1543-1550
Shenoy, Niraj; Creagan, Edward; Witzig, Thomas et al. (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 34:700-706
Maurer, M J; Habermann, T M; Shi, Q et al. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29:1822-1827

Showing the most recent 10 out of 387 publications